Symptom Burden According to Dialysis Day of the Week in Three Times a Week Haemodialysis Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Sep 27

PMID 36166424

Authors

Pann Ei Hnynn Si

Rachel Gair

Tania Barnes

Louese Dunn

Sonia Lee

Steven Ariss

Stephen J Walters

Martin Wilkie

James Fotheringham

Affiliations

Soon will be listed here.

Abstract

Background: Haemodialysis patients experience significant symptom burden and effects on health-related quality of life. Studies have shown increases in fluid overload, hospitalization and mortality immediately after the long interdialytic interval in thrice weekly in-centre haemodialysis patients, however the relationship between the dialytic interval and patient reported outcome measures (PROMs) has not been quantified and the extent to which dialysis day of PROM completion needs to be standardised is unknown.

Methods: Three times a week haemodialysis patients participating in a stepped wedge trial to increase patient participation in haemodialysis tasks completed PROMs (POS-S Renal symptom score and EQ-5D-5L) at recruitment, six, 12 and 18 months. Time from the long interdialytic interval, HD day of the week, and HD days vs non-HD days were included in mixed effects Linear Regression, estimating severity (none to overwhelming treated as 0 to 4) of 17 symptoms and EQ-5D-5L, adjusting for age, sex, time on HD, control versus intervention and Charlson Comorbidity Score.

Results: 517 patients completed 1659 YHS questionnaires that could be assigned HD day (510 on Mon/Tue/Sun, 549 on Wed/Thu/Tue, 308 on Fri/Sat/Thu and 269 on non-HD days). With the exception of restless legs and skin changes, there was no statistically significant change in symptom severity or EQ-5D-5L with increasing time from the long interdialytic interval. Patients who responded on non-HD days had higher severity of poor appetite, constipation, difficulty sleeping, poor mobility and depression (approximately 0.2 severity level), and lower EQ-5D-5L (-0.06, CI -0.09 to -0.03) compared to HD days.

Conclusions: Measuring symptom severity and EQ-5D-5L in haemodialysis populations does not need to account for dialysis schedule, but completion either on HD or non-HD days could introduce bias that may impact evaluation of interventions. Researchers should ensure completion of these instruments are standardized on either dialysis or non-dialysis days.

Citing Articles

Consensus document on palliative care in cardiorenal patients.

Bonanad C, Buades J, Leiva J, de la Espriella R, Marcos M, Nunez J Front Cardiovasc Med. 2024; 10:1225823.

PMID: 38179502 PMC: 10766370. DOI: 10.3389/fcvm.2023.1225823.

The trajectory of a range of commonly captured symptoms with standard care in people with kidney failure receiving haemodialysis: consideration for clinical trial design.

Si P, Hernandez-Alava M, Dunn L, Wilkie M, Fotheringham J BMC Nephrol. 2023; 24(1):341.

PMID: 37978349 PMC: 10656962. DOI: 10.1186/s12882-023-03394-w.

References

Foley R, Gilbertson D, Murray T, Collins A . Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011; 365(12):1099-107. DOI: 10.1056/NEJMoa1103313. View

Fotheringham J, Latimer N, Froissart M, Kronenberg F, Stenvinkel P, Floege J . Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. Clin Kidney J. 2021; 14(2):665-672. PMC: 7886573. DOI: 10.1093/ckj/sfaa250. View

Walters S, Brazier J . Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005; 14(6):1523-32. DOI: 10.1007/s11136-004-7713-0. View

Pyart R, Evans K, Steenkamp R, Casula A, Wong E, Magadi W . The 21st UK Renal Registry Annual Report: A Summary of Analyses of Adult Data in 2017. Nephron. 2019; 144(2):59-66. DOI: 10.1159/000504851. View

Mapes D, Bragg-Gresham J, Bommer J, Fukuhara S, McKevitt P, Wikstrom B . Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44(5 Suppl 2):54-60. DOI: 10.1053/j.ajkd.2004.08.012. View

Megari K . Quality of Life in Chronic Disease Patients. Health Psychol Res. 2016; 1(3):e27. PMC: 4768563. DOI: 10.4081/hpr.2013.e27. View

Joshi V . Quality of life in end stage renal disease patients. World J Nephrol. 2014; 3(4):308-16. PMC: 4220366. DOI: 10.5527/wjn.v3.i4.308. View

Hemmelgarn B, Manns B, Quan H, Ghali W . Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis. 2003; 42(1):125-32. DOI: 10.1016/s0272-6386(03)00415-3. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

10.

Hernandez A, Steyerberg E, Habbema J . Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. J Clin Epidemiol. 2004; 57(5):454-60. DOI: 10.1016/j.jclinepi.2003.09.014. View

11.

Osthus T, Preljevic V, Sandvik L, Leivestad T, Nordhus I, Dammen T . Mortality and health-related quality of life in prevalent dialysis patients: Comparison between 12-items and 36-items short-form health survey. Health Qual Life Outcomes. 2012; 10:46. PMC: 3464967. DOI: 10.1186/1477-7525-10-46. View

12.

Schott J, Bartlett J, Barnes J, Leung K, Ourselin S, Fox N . Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging. 2010; 31(8):1452-62, 1462.e1-2. PMC: 2947486. DOI: 10.1016/j.neurobiolaging.2010.04.011. View

13.

Fotheringham J, Barnes T, Dunn L, Lee S, Ariss S, Young T . A breakthrough series collaborative to increase patient participation with hemodialysis tasks: A stepped wedge cluster randomised controlled trial. PLoS One. 2021; 16(7):e0253966. PMC: 8291659. DOI: 10.1371/journal.pone.0253966. View

14.

Revicki D, Hays R, Cella D, Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008; 61(2):102-9. DOI: 10.1016/j.jclinepi.2007.03.012. View

15.

Astrup G, Rustoen T, Hofso K, Gran J, Bjordal K . Symptom burden and patient characteristics: Association with quality of life in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2017; 39(10):2114-2126. DOI: 10.1002/hed.24875. View

16.

Feldman R, Berman N, Reid M, Roberts J, Shengelia R, Christianer K . Improving symptom management in hemodialysis patients: identifying barriers and future directions. J Palliat Med. 2013; 16(12):1528-33. PMC: 3868261. DOI: 10.1089/jpm.2013.0176. View

17.

Weisbord S, Fried L, Arnold R, Rotondi A, Fine M, Levenson D . Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage. 2004; 27(3):226-40. DOI: 10.1016/j.jpainsymman.2003.07.004. View

18.

Moskovitch J, Mount P, Davies M . Changes in Symptom Burden in Dialysis Patients Assessed Using a Symptom-Reporting Questionnaire in Clinic. J Palliat Care. 2019; 35(1):59-65. DOI: 10.1177/0825859719827315. View

19.

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

20.

Senanayake S, Gunawardena N, Palihawadana P, Bandara P, Haniffa R, Karunarathna R . Symptom burden in chronic kidney disease; a population based cross sectional study. BMC Nephrol. 2017; 18(1):228. PMC: 5504715. DOI: 10.1186/s12882-017-0638-y. View